GBT Announces Participation in Upcoming Investor Conferences
July 30 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that members of the senior management team will participate in
virtual fireside chats at the following investor conferences:
- William Blair Biotech Focus Conference 2020 on August 6 at 3:00
p.m. ET;
- Wedbush PacGrow Healthcare Virtual Conference on August 11 at
2:55 p.m. ET; and
- Canaccord Genuity 40th Annual Growth Virtual Conference on
August 13 at 1:30 p.m. ET.
The fireside chats will be webcast live from GBT’s website at
www.gbt.com in the Investors section. Replays of the webcast will
be archived and available for one month following the event.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to the
discovery, development, and delivery of life-changing treatments
that provide hope to underserved patient communities. Founded in
2011, GBT is delivering on its goal to transform the treatment and
care of sickle cell disease (SCD), a lifelong, devastating
inherited blood disorder. The company has introduced Oxbryta®
(voxelotor), the first FDA-approved treatment that directly
inhibits sickle hemoglobin polymerization, the root cause of red
blood cell sickling in SCD. GBT is also advancing its pipeline
program in SCD with inclacumab, a p-selectin inhibitor in
development to address pain crises associated with the disease. In
addition, GBT’s drug discovery teams are working on new targets to
develop the next generation of treatments for SCD. To learn more,
please visit www.gbt.com and follow the company on Twitter
@GBT_news.
Contact
Information:
Steven Immergut (media)650-410-3258simmergut@gbt.com
Stephanie Yao (investors) 650-741-7730 syao@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024